A novartis quality worker poses for a portrait

Reimagining medicine by transforming cancer care

At Novartis, we focus on five key cancer areas where we have identified patient needs and promise within our portfolio – breast cancer, lung cancer, melanoma, kidney cancer and hematology.

Breast Cancer

For more than 25 years, we have been at the forefront of driving scientific advancements and improving clinical practice in collaboration with the global breast cancer community. With one of the most diverse breast cancer pipelines and the largest number of compounds in development, Novartis leads the industry in discovery of new therapies and combinations.

Lung Cancer

Over the past decade, our research has supported the evolution of treatment approaches for patients living with mutation-driven types of lung cancer. We remain focused on the global lung cancer community through ongoing studies as well as the exploration of investigational compounds that target genomic biomarkers.  


Melanoma is the most serious type of skin cancer, and in many cases is caused by damage to the DNA in skin cells; more than half of melanoma cases are caused by these genetic changes. Through research, investigational studies and advocacy, Novartis brings attention and support to those battling advanced melanoma.  

Kidney Cancer

Novartis has a strong heritage in the research, development and discovery of treatments for advanced renal cell carcinoma (RCC). RCC is the most common type of kidney cancer, accounting for 90% of all kidney tumors.  


We are passionate about our work for patients with life-threatening blood cancers and serious non-cancer blood disorders. Together with the medical community, we are reimagining hematology.  

Novartis Oncology
“We see great potential for the future of cancer research by targeting cancer pathways, harnessing the power of the immune system, and combining both approaches.”
Bruno Strigini CEO, Novartis Oncology, Novartis Innovative Medicines